Tag Archives: Canada
#439110 Robotic Exoskeletons Could One Day Walk ...
Engineers, using artificial intelligence and wearable cameras, now aim to help robotic exoskeletons walk by themselves.
Increasingly, researchers around the world are developing lower-body exoskeletons to help people walk. These are essentially walking robots users can strap to their legs to help them move.
One problem with such exoskeletons: They often depend on manual controls to switch from one mode of locomotion to another, such as from sitting to standing, or standing to walking, or walking on the ground to walking up or down stairs. Relying on joysticks or smartphone apps every time you want to switch the way you want to move can prove awkward and mentally taxing, says Brokoslaw Laschowski, a robotics researcher at the University of Waterloo in Canada.
Scientists are working on automated ways to help exoskeletons recognize when to switch locomotion modes — for instance, using sensors attached to legs that can detect bioelectric signals sent from your brain to your muscles telling them to move. However, this approach comes with a number of challenges, such as how how skin conductivity can change as a person’s skin gets sweatier or dries off.
Now several research groups are experimenting with a new approach: fitting exoskeleton users with wearable cameras to provide the machines with vision data that will let them operate autonomously. Artificial intelligence (AI) software can analyze this data to recognize stairs, doors, and other features of the surrounding environment and calculate how best to respond.
Laschowski leads the ExoNet project, the first open-source database of high-resolution wearable camera images of human locomotion scenarios. It holds more than 5.6 million images of indoor and outdoor real-world walking environments. The team used this data to train deep-learning algorithms; their convolutional neural networks can already automatically recognize different walking environments with 73 percent accuracy “despite the large variance in different surfaces and objects sensed by the wearable camera,” Laschowski notes.
According to Laschowski, a potential limitation of their work their reliance on conventional 2-D images, whereas depth cameras could also capture potentially useful distance data. He and his collaborators ultimately chose not to rely on depth cameras for a number of reasons, including the fact that the accuracy of depth measurements typically degrades in outdoor lighting and with increasing distance, he says.
In similar work, researchers in North Carolina had volunteers with cameras either mounted on their eyeglasses or strapped onto their knees walk through a variety of indoor and outdoor settings to capture the kind of image data exoskeletons might use to see the world around them. The aim? “To automate motion,” says Edgar Lobaton an electrical engineering researcher at North Carolina State University. He says they are focusing on how AI software might reduce uncertainty due to factors such as motion blur or overexposed images “to ensure safe operation. We want to ensure that we can really rely on the vision and AI portion before integrating it into the hardware.”
In the future, Laschowski and his colleagues will focus on improving the accuracy of their environmental analysis software with low computational and memory storage requirements, which are important for onboard, real-time operations on robotic exoskeletons. Lobaton and his team also seek to account for uncertainty introduced into their visual systems by movements .
Ultimately, the ExoNet researchers want to explore how AI software can transmit commands to exoskeletons so they can perform tasks such as climbing stairs or avoiding obstacles based on a system’s analysis of a user's current movements and the upcoming terrain. With autonomous cars as inspiration, they are seeking to develop autonomous exoskeletons that can handle the walking task without human input, Laschowski says.
However, Laschowski adds, “User safety is of the utmost importance, especially considering that we're working with individuals with mobility impairments,” resulting perhaps from advanced age or physical disabilities.
“The exoskeleton user will always have the ability to override the system should the classification algorithm or controller make a wrong decision.” Continue reading
Posted in Human Robots
#437673 Can AI and Automation Deliver a COVID-19 ...
Illustration: Marysia Machulska
Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.
“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.
In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.
Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.
There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”
That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.
“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”
There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.
Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, antivirals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.
The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.
But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.
Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.
And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.
While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”
Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.
Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.
Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.
And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.
To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”
Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.
1/5
STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot
2/5
STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.
3/5
STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.
4/5
STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.
5/5
STEP 5: The most promising compounds are tested against live virus samples.
Previous
Next
Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.
For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.
The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.
Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.
That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.
First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.
Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.
Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.
Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s AI-generated molecules in virtual reality.
Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.
Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.
Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.
Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.
The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.
Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.
Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.
While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.
In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.
“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.
While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.
“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”
This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading
Posted in Human Robots
#436414 Japanese Researchers Teaching Robots to ...
When mobile manipulators eventually make it into our homes, self-repair is going to be a very important function. Hopefully, these robots will be durable enough that they won’t need to be repaired very often, but from time to time they’ll almost certainly need minor maintenance. At Humanoids 2019 in Toronto, researchers from the University of Tokyo showed how they taught a PR2 to perform simple repairs on itself by tightening its own screws. And using that skill, the robot was also able to augment itself, adding accessories like hooks to help it carry more stuff. Clever robot!
To keep things simple, the researchers provided the robot with CAD data that tells it exactly where all of its screws are.
At the moment, the robot can’t directly detect on its own whether a particular screw needs tightening, although it can tell if its physical pose doesn’t match its digital model, which suggests that something has gone wonky. It can also check its screws autonomously from time to time, or rely on a human physically pointing out that it has a screw loose, using the human’s finger location to identify which screw it is. Another challenge is that most robots, like most humans, are limited in the areas on themselves that they can comfortably reach. So to tighten up everything, they might have to find themselves a robot friend to help, just like humans help each other put on sunblock.
The actual tightening is either super easy or quite complicated, depending on the location and orientation of the screw. If the robot is lucky, it can just use its continuous wrist rotation for tightening, but if a screw is located in a tight position that requires an Allen wrench, the robot has to regrasp the tool over and over as it incrementally tightens the screw.
Image: University of Tokyo
In one experiment, the researchers taught a PR2 robot to attach a hook to one of its shoulders. The robot uses one hand to grasp the hook and another hand to grasp a screwdriver. The researchers tested the hook by hanging a tote bag on it.
The other neat trick that a robot can do once it can tighten screws on its own body is to add new bits of hardware to itself. PR2 was thoughtfully designed with mounting points on its shoulders (or maybe technically its neck) and head, and it turns out that it can reach these points with its manipulators, allowing to modify itself, as the researchers explain:
When PR2 wants to have a lot of things, the only two hands are not enough to realize that. So we let PR2 to use a bag the same as we put it on our shoulder. PR2 started attaching the hook whose pose is calculated with self CAD data with a driver on his shoulder in order to put a bag on his shoulder. PR2 finished attaching the hook, and the people put a lot of cans in a tote bag and put it on PR2’s shoulder.
“Self-Repair and Self-Extension by Tightening Screws based on Precise Calculation of Screw Pose of Self-Body with CAD Data and Graph Search with Regrasping a Driver,” by Takayuki Murooka, Kei Okada, and Masayuki Inaba from the University of Tokyo, was presented at Humanoids 2019 in Toronto, Canada. Continue reading
Posted in Human Robots
#436042 Video Friday: Caltech’s Drone With ...
Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here’s what we have so far (send us your events!):
ISRR 2019 – October 6-10, 2019 – Hanoi, Vietnam
Ro-Man 2019 – October 14-18, 2019 – New Delhi, India
Humanoids 2019 – October 15-17, 2019 – Toronto, Canada
ARSO 2019 – October 31-1, 2019 – Beijing, China
ROSCon 2019 – October 31-1, 2019 – Macau
IROS 2019 – November 4-8, 2019 – Macau
Let us know if you have suggestions for next week, and enjoy today’s videos.
Caltech has been making progress on LEONARDO (LEg ON Aerial Robotic DrOne), their leggy thruster powered humanoid-thing. It can now balance and walk, which is quite impressive to see.
We’ll circle back again when they’ve got it jumping and floating around.
[ Caltech ]
Turn the subtitles on to learn how robots became experts at slicing bubbly, melty, delicious cheese.
These robots learned how to do the traditional Swiss raclette from demonstration. The Robot Learning & Interaction group at the Idiap Research Institute has developed an imitation learning technique allowing the robot to acquire new skills by considering position and force information, with an automatic adaptation to new situations. The range of applications is wide, including industrial robots, service robots, and assistive robots.
[ Idiap ]
Thanks Sylvain!
Some amazing news this week from Skydio, with the announcement of their better in every single way Skydio 2 autonomous drone. Read our full article for details, but here’s a getting started video that gives you an overview of what the drone can do.
The first batch sold out in 36 hours, but you can put down a $100 deposit to reserve the $999 drone for 2020 delivery.
[ Skydio ]
UBTECH is introducing a couple new robot kits for the holidays: ChampBot and FireBot.
$130 each, available on October 20.
[ Ubtech ]
NASA’s InSight lander on Mars is trying to use its robotic arm to get the mission’s heat flow probe, or mole, digging again. InSight team engineer Ashitey Trebbi-Ollennu, based at NASA’s Jet Propulsion Laboratory in Pasadena, California, explains what has been attempted and the game plan for the coming weeks. The next tactic they’ll try will be “pinning” the mole against the hole it’s in.
[ NASA ]
We introduce shape-changing swarm robots. A swarm of self-transformable robots can both individually and collectively change their configuration to display information, actuate objects, act as tangible controllers, visualize data, and provide physical affordances. ShapeBots is a concept prototype of shape-changing swarm robots. Each robot can change its shape by leveraging small linear actuators that are thin (2.5 cm) and highly extendable (up to 20cm) in both horizontal and vertical directions.
[ Ryo Suzuki ]
Robot abuse!
Vision 60 legged robot managing unstructured terrain without vision or force sensors in its legs. Using only high-transparency actuators and 2kHz algorithmic stability control… 4-limbs and 12-motors with only a velocity command.
[ Ghost Robotics ]
We asked real people to bring in real products they needed picked for their application. In MINUTES, we assembled the right tool.
This is a cool idea, but for a real challenge they should try it outside a supermarket. Or a pet store.
[ Soft Robotics ]
Good water quality is important to humans and to nature. In a country with as much water as the Netherlands has, ensuring water quality is a very labour-intensive undertaking. To address this issue, researchers from TU Delft have developed a ‘pelican drone’: a drone capable of taking water samples quickly, in combination with a measuring instrument that immediately analyses the water quality. The drone was tested this week at the new Marker Wadden nature area ‘Living Lab’.
[ MAVLab ]
In an international collaboration led by scientists in Switzerland, three amputees merge with their bionic prosthetic legs as they climb over various obstacles without having to look. The amputees report using and feeling their bionic leg as part of their own body, thanks to sensory feedback from the prosthetic leg that is delivered to nerves in the leg’s stump.
[ EPFL ]
It’s a little hard to see, but this is one way of testing out asteroid imaging spacecraft without actually going into space: a fake asteroid and a 2D microgravity simulator.
[ Caltech ]
Drones can help filmmakers do the kinds of shots that would be otherwise impossible.
[ DJI ]
Two long interviews this week from Lex Fridman’s AI Podcast, and both of them are worth watching: Gary Marcus, and Peter Norvig.
[ AI Podcast ]
This week’s CMU RI Seminar comes from Tucker Hermans at the University of Utah, on “Improving Multi-fingered Robot Manipulation by Unifying Learning and Planning.”
Multi-fingered hands offer autonomous robots increased dexterity, versatility, and stability over simple two-fingered grippers. Naturally, this increased ability comes with increased complexity in planning and executing manipulation actions. As such, I propose combining model-based planning with learned components to improve over purely data-driven or purely-model based approaches to manipulation. This talk examines multi-fingered autonomous manipulation when the robot has only partial knowledge of the object of interest. I will first present results on planning multi-fingered grasps for novel objects using a learned neural network. I will then present our approach to planning in-hand manipulation tasks when dynamic properties of objects are not known. I will conclude with a discussion of our ongoing and future research to further unify these two approaches.
[ CMU RI ] Continue reading
Posted in Human Robots